Try our Advanced Search for more refined results

INTERNATIONAL UNION OF BRICKLAYERS AND ALLIED CRAFT WORKERS LOCAL 1 HEALTH FUND v. CELGENE CORPORATION

  1. May 21, 2020

    Drug Buyers' Retooled $34M Celgene Deal Wins Initial OK

    A New Jersey federal judge has given the preliminary green light to a $34 million deal between drug buyers and Bristol-Myers Squibb unit Celgene over allegations the drugmaker illegally monopolized a pair of cancer treatments.

  2. April 07, 2020

    Drug Buyers Cut New, Smaller Antitrust Deal With Celgene

    Consumers, cities and union benefits are taking another shot at settling class action claims that Bristol-Myers Squibb's Celgene unit monopolized cancer drugs by proposing a pared down $34 million deal that excludes the class members whose opt outs spurred Celgene to scrap the original settlement.

  3. January 08, 2020

    Drug Buyers 'Astounded' As Celgene Axes $55M Antitrust Deal

    Bristol-Myers Squibb's Celgene unit has dropped out of a $55 million deal that would have ended litigation alleging a sweeping scheme to monopolize the market for two cancer drugs that have racked up tens of billions of dollars in sales.

  4. July 24, 2019

    Celgene To Pay $55M Over Cancer Drug Monopoly Claims

    Celgene Corp. on Wednesday agreed to cut a check for $55 million to end a proposed class action alleging a sweeping scheme to monopolize the market for two cancer drugs that have racked up tens of billions of dollars in sales.

  5. January 29, 2019

    Celgene Says Drug Buyers' Second Try For Cert. No Better

    A proposed class of drug buyers accusing Celgene Corp. of creating a monopoly on two of its drugs shouldn't get a second crack at class certification, the biopharmaceutical company told a New Jersey federal court Monday.

  6. November 01, 2018

    Celgene's Bid To Trim Drug Monopoly Suit Denied

    A suit accusing biopharmaceutical firm Celgene Corp. of locking two competing generic drugs out of the market remains intact in New Jersey federal court, after a judge has refused to toss claims under state laws not currently at issue in the dispute.

  7. October 30, 2018

    Celgene Corp. Drug Buyers Denied Cert. In Antitrust Suit

    A New Jersey federal judge Tuesday declined to certify a proposed consumer class in antitrust litigation accusing Celgene Corp. of creating a monopoly on two of its drugs, finding that the proposed class includes a large number of uninjured members.